| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms, Experimental | 12 | 2019 | 261 | 1.970 |
Why?
|
| Immunotherapy | 12 | 2025 | 819 | 1.940 |
Why?
|
| Immunotherapy, Adoptive | 8 | 2025 | 327 | 1.510 |
Why?
|
| Neoplasms | 19 | 2025 | 3334 | 1.500 |
Why?
|
| Radiotherapy | 5 | 2020 | 325 | 1.410 |
Why?
|
| Dendritic Cells | 16 | 2024 | 552 | 1.090 |
Why?
|
| CD8-Positive T-Lymphocytes | 9 | 2025 | 696 | 1.040 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2019 | 168 | 0.980 |
Why?
|
| Tumor Escape | 5 | 2017 | 55 | 0.980 |
Why?
|
| Adoptive Transfer | 3 | 2017 | 174 | 0.980 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2025 | 92 | 0.830 |
Why?
|
| Myeloid Cells | 2 | 2015 | 121 | 0.810 |
Why?
|
| Interferon-gamma | 8 | 2019 | 479 | 0.780 |
Why?
|
| Genetic Therapy | 8 | 2015 | 373 | 0.750 |
Why?
|
| Cell Line, Tumor | 15 | 2025 | 2888 | 0.620 |
Why?
|
| Radioimmunotherapy | 1 | 2020 | 29 | 0.610 |
Why?
|
| Antibodies, Monoclonal | 9 | 2009 | 1416 | 0.590 |
Why?
|
| Animals | 44 | 2025 | 28902 | 0.550 |
Why?
|
| Killer Cells, Natural | 7 | 2012 | 297 | 0.520 |
Why?
|
| Tumor Microenvironment | 4 | 2023 | 617 | 0.520 |
Why?
|
| Mice | 32 | 2025 | 12697 | 0.520 |
Why?
|
| Interleukin-15 | 4 | 2012 | 78 | 0.510 |
Why?
|
| Vascular Remodeling | 1 | 2017 | 24 | 0.510 |
Why?
|
| Blood Vessels | 1 | 2017 | 92 | 0.500 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 6 | 2009 | 17 | 0.490 |
Why?
|
| Cell Hypoxia | 1 | 2017 | 191 | 0.480 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2017 | 502 | 0.480 |
Why?
|
| T-Lymphocytes | 7 | 2015 | 1327 | 0.470 |
Why?
|
| Cancer-Associated Fibroblasts | 1 | 2016 | 44 | 0.470 |
Why?
|
| Cell Communication | 2 | 2015 | 222 | 0.460 |
Why?
|
| Mice, Inbred C57BL | 19 | 2019 | 3598 | 0.450 |
Why?
|
| B7-H1 Antigen | 2 | 2017 | 332 | 0.450 |
Why?
|
| Ischemia | 1 | 2017 | 262 | 0.440 |
Why?
|
| Mice, Knockout | 7 | 2024 | 2207 | 0.390 |
Why?
|
| Chemoradiotherapy | 1 | 2016 | 337 | 0.390 |
Why?
|
| Receptors, Nerve Growth Factor | 4 | 2006 | 13 | 0.380 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 665 | 0.370 |
Why?
|
| Receptors, Tumor Necrosis Factor | 4 | 2006 | 85 | 0.370 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2013 | 291 | 0.350 |
Why?
|
| Colonic Neoplasms | 5 | 2018 | 582 | 0.350 |
Why?
|
| Membrane Proteins | 5 | 2024 | 1285 | 0.340 |
Why?
|
| Melanoma, Experimental | 3 | 2024 | 114 | 0.330 |
Why?
|
| Interleukin-12 | 5 | 2005 | 110 | 0.320 |
Why?
|
| Liver | 3 | 2012 | 1231 | 0.310 |
Why?
|
| Macrophages | 1 | 2013 | 643 | 0.310 |
Why?
|
| Antigens, Neoplasm | 5 | 2017 | 361 | 0.310 |
Why?
|
| Antigens, CD | 9 | 2008 | 484 | 0.290 |
Why?
|
| Combined Modality Therapy | 5 | 2020 | 1751 | 0.290 |
Why?
|
| Plasmacytoma | 1 | 2008 | 26 | 0.290 |
Why?
|
| Tumor Burden | 3 | 2017 | 333 | 0.270 |
Why?
|
| Adjuvants, Immunologic | 1 | 2008 | 176 | 0.260 |
Why?
|
| NF-kappa B | 2 | 2021 | 423 | 0.250 |
Why?
|
| Interferon Type I | 2 | 2024 | 170 | 0.250 |
Why?
|
| Mice, Transgenic | 9 | 2019 | 1604 | 0.240 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2025 | 556 | 0.230 |
Why?
|
| T-Lymphocytes, Cytotoxic | 5 | 2012 | 321 | 0.220 |
Why?
|
| RNA-Binding Proteins | 2 | 2024 | 324 | 0.210 |
Why?
|
| Multiple Myeloma | 1 | 2008 | 369 | 0.200 |
Why?
|
| Isoantigens | 1 | 2004 | 74 | 0.200 |
Why?
|
| Green Fluorescent Proteins | 4 | 2016 | 310 | 0.200 |
Why?
|
| Cell Movement | 3 | 2019 | 814 | 0.200 |
Why?
|
| Immunologic Memory | 3 | 2013 | 188 | 0.190 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2016 | 218 | 0.190 |
Why?
|
| Cancer Vaccines | 3 | 2013 | 168 | 0.190 |
Why?
|
| Lymphocyte Count | 2 | 2017 | 99 | 0.190 |
Why?
|
| Environment | 1 | 2005 | 233 | 0.190 |
Why?
|
| Adenoviridae | 6 | 2006 | 340 | 0.190 |
Why?
|
| Spleen | 4 | 2012 | 375 | 0.180 |
Why?
|
| Lymphocyte Activation | 3 | 2016 | 822 | 0.180 |
Why?
|
| Humans | 30 | 2025 | 98135 | 0.180 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 1566 | 0.170 |
Why?
|
| Radiation Tolerance | 2 | 2019 | 179 | 0.170 |
Why?
|
| Metal-Organic Frameworks | 1 | 2021 | 24 | 0.170 |
Why?
|
| Transforming Growth Factor beta | 1 | 2023 | 356 | 0.170 |
Why?
|
| CDC2 Protein Kinase | 1 | 2021 | 46 | 0.170 |
Why?
|
| Erythroid Precursor Cells | 1 | 2021 | 33 | 0.170 |
Why?
|
| Mice, Inbred BALB C | 7 | 2009 | 1110 | 0.160 |
Why?
|
| CTLA-4 Antigen | 5 | 2008 | 146 | 0.160 |
Why?
|
| Neutrophils | 1 | 2021 | 346 | 0.150 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2020 | 105 | 0.150 |
Why?
|
| Receptors, Chemokine | 2 | 2013 | 30 | 0.150 |
Why?
|
| Immunization | 4 | 2013 | 154 | 0.150 |
Why?
|
| Disease Models, Animal | 4 | 2018 | 2572 | 0.150 |
Why?
|
| Pancreatic Neoplasms | 3 | 2016 | 769 | 0.140 |
Why?
|
| Transfection | 5 | 2008 | 883 | 0.140 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2018 | 20 | 0.140 |
Why?
|
| Receptors, Interferon | 2 | 2017 | 33 | 0.140 |
Why?
|
| Mice, Inbred C3H | 3 | 2013 | 370 | 0.140 |
Why?
|
| Cell Survival | 2 | 2019 | 1014 | 0.140 |
Why?
|
| Gene Transfer Techniques | 2 | 2012 | 155 | 0.140 |
Why?
|
| Glioblastoma | 1 | 2021 | 299 | 0.140 |
Why?
|
| Flow Cytometry | 6 | 2012 | 720 | 0.130 |
Why?
|
| Antigens, Differentiation | 4 | 2006 | 125 | 0.130 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2018 | 237 | 0.130 |
Why?
|
| Intravital Microscopy | 1 | 2017 | 15 | 0.130 |
Why?
|
| Immunity, Innate | 2 | 2018 | 481 | 0.130 |
Why?
|
| Necrosis | 1 | 2017 | 212 | 0.120 |
Why?
|
| Antigen Presentation | 4 | 2021 | 234 | 0.120 |
Why?
|
| Substrate Specificity | 1 | 2017 | 374 | 0.120 |
Why?
|
| Stromal Cells | 1 | 2017 | 153 | 0.120 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2017 | 174 | 0.120 |
Why?
|
| Collagen Type I | 1 | 2016 | 75 | 0.120 |
Why?
|
| Female | 13 | 2025 | 51570 | 0.120 |
Why?
|
| eIF-2 Kinase | 1 | 2015 | 52 | 0.110 |
Why?
|
| Recombinant Proteins | 4 | 2012 | 993 | 0.110 |
Why?
|
| Immunomodulation | 1 | 2015 | 64 | 0.110 |
Why?
|
| Brain Neoplasms | 1 | 2021 | 842 | 0.110 |
Why?
|
| Nucleotidyltransferases | 1 | 2014 | 32 | 0.110 |
Why?
|
| Wound Healing | 1 | 2017 | 384 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2021 | 1394 | 0.110 |
Why?
|
| Cytokines | 2 | 2017 | 889 | 0.100 |
Why?
|
| Skin Window Technique | 1 | 2013 | 3 | 0.100 |
Why?
|
| Models, Immunological | 2 | 2005 | 86 | 0.100 |
Why?
|
| Radiosurgery | 1 | 2018 | 351 | 0.100 |
Why?
|
| CD11b Antigen | 1 | 2013 | 35 | 0.100 |
Why?
|
| Vaccination | 1 | 2016 | 323 | 0.100 |
Why?
|
| Endothelial Cells | 1 | 2017 | 500 | 0.100 |
Why?
|
| Melanoma | 1 | 2018 | 524 | 0.100 |
Why?
|
| Bacterial Vaccines | 1 | 2013 | 44 | 0.100 |
Why?
|
| Models, Biological | 2 | 2013 | 1809 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2015 | 446 | 0.100 |
Why?
|
| Immunity, Cellular | 3 | 2018 | 187 | 0.100 |
Why?
|
| Actins | 1 | 2016 | 480 | 0.100 |
Why?
|
| DNA | 2 | 2018 | 1274 | 0.090 |
Why?
|
| Cell Adhesion Molecules | 2 | 2003 | 184 | 0.090 |
Why?
|
| Lipoproteins, HDL | 1 | 2012 | 92 | 0.090 |
Why?
|
| Cell Proliferation | 3 | 2018 | 1790 | 0.090 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2013 | 199 | 0.090 |
Why?
|
| Neovascularization, Pathologic | 1 | 2013 | 356 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 1099 | 0.090 |
Why?
|
| Breast Neoplasms | 1 | 2025 | 3272 | 0.080 |
Why?
|
| CD40 Antigens | 2 | 2008 | 43 | 0.080 |
Why?
|
| Survival Analysis | 2 | 2016 | 1527 | 0.080 |
Why?
|
| Receptors, Immunologic | 2 | 2007 | 142 | 0.080 |
Why?
|
| Homeodomain Proteins | 1 | 2013 | 566 | 0.080 |
Why?
|
| Leukocyte Common Antigens | 1 | 2009 | 50 | 0.080 |
Why?
|
| Cross-Priming | 3 | 2015 | 59 | 0.070 |
Why?
|
| Neoplasm Metastasis | 3 | 2020 | 1089 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2020 | 9713 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 889 | 0.070 |
Why?
|
| Genes, RAG-1 | 1 | 2008 | 11 | 0.070 |
Why?
|
| Injections, Intravenous | 1 | 2008 | 212 | 0.070 |
Why?
|
| DNA-Binding Proteins | 1 | 2013 | 1255 | 0.070 |
Why?
|
| Parkinsonian Disorders | 1 | 2007 | 24 | 0.060 |
Why?
|
| Adaptive Immunity | 2 | 2021 | 193 | 0.060 |
Why?
|
| Microglia | 1 | 2007 | 131 | 0.060 |
Why?
|
| Radiation, Ionizing | 2 | 2018 | 123 | 0.060 |
Why?
|
| Bone Marrow Cells | 1 | 2007 | 269 | 0.060 |
Why?
|
| B7-1 Antigen | 1 | 2006 | 75 | 0.060 |
Why?
|
| Peritoneal Neoplasms | 1 | 2007 | 195 | 0.060 |
Why?
|
| Transgenes | 1 | 2006 | 173 | 0.060 |
Why?
|
| Viral Hepatitis Vaccines | 1 | 2005 | 6 | 0.060 |
Why?
|
| Interleukin-8 | 1 | 2005 | 90 | 0.060 |
Why?
|
| Virus Diseases | 1 | 2006 | 83 | 0.060 |
Why?
|
| Immune Tolerance | 2 | 2005 | 386 | 0.050 |
Why?
|
| Genetic Engineering | 1 | 2005 | 102 | 0.050 |
Why?
|
| Hepacivirus | 1 | 2005 | 137 | 0.050 |
Why?
|
| Viral Core Proteins | 1 | 2003 | 24 | 0.050 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2004 | 112 | 0.050 |
Why?
|
| Viral Envelope Proteins | 1 | 2003 | 80 | 0.050 |
Why?
|
| Adenine | 1 | 2023 | 101 | 0.050 |
Why?
|
| Tissue Engineering | 1 | 2004 | 204 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 2 | 2021 | 512 | 0.050 |
Why?
|
| Apoptosis | 2 | 2006 | 1752 | 0.050 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2002 | 72 | 0.050 |
Why?
|
| Mastitis, Bovine | 1 | 2001 | 1 | 0.040 |
Why?
|
| Liver Neoplasms | 2 | 2006 | 831 | 0.040 |
Why?
|
| Macrophage-1 Antigen | 1 | 2001 | 18 | 0.040 |
Why?
|
| Gene Expression | 1 | 2006 | 1320 | 0.040 |
Why?
|
| Base Sequence | 2 | 2021 | 2222 | 0.040 |
Why?
|
| CD3 Complex | 1 | 2001 | 137 | 0.040 |
Why?
|
| Carcinoma | 1 | 2004 | 440 | 0.040 |
Why?
|
| Ovalbumin | 2 | 2013 | 105 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 3 | 2011 | 1028 | 0.040 |
Why?
|
| Mammary Glands, Animal | 1 | 2001 | 82 | 0.040 |
Why?
|
| Antigen-Presenting Cells | 1 | 2021 | 146 | 0.040 |
Why?
|
| Immunoconjugates | 1 | 2002 | 138 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2007 | 1646 | 0.040 |
Why?
|
| Male | 5 | 2018 | 47109 | 0.040 |
Why?
|
| Interferon-beta | 2 | 2014 | 128 | 0.040 |
Why?
|
| Antineoplastic Agents | 2 | 2014 | 2373 | 0.040 |
Why?
|
| Peptide Fragments | 2 | 2013 | 480 | 0.040 |
Why?
|
| Chromosomal Instability | 1 | 2018 | 22 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2007 | 1103 | 0.040 |
Why?
|
| Transcription Factor RelA | 1 | 2018 | 39 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2006 | 1211 | 0.040 |
Why?
|
| Binding Sites | 1 | 2021 | 1159 | 0.030 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 61 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2018 | 193 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2021 | 977 | 0.030 |
Why?
|
| Receptors, Natural Killer Cell | 2 | 2007 | 20 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 373 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2018 | 479 | 0.030 |
Why?
|
| Chemokines | 1 | 2016 | 79 | 0.030 |
Why?
|
| Homeostasis | 1 | 2018 | 474 | 0.030 |
Why?
|
| Bystander Effect | 1 | 2015 | 14 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2018 | 3621 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2014 | 2855 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2023 | 1717 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 2 | 2007 | 286 | 0.030 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2015 | 99 | 0.030 |
Why?
|
| Point Mutation | 1 | 2015 | 237 | 0.030 |
Why?
|
| Xanthones | 1 | 2014 | 10 | 0.030 |
Why?
|
| Nucleotides, Cyclic | 1 | 2014 | 13 | 0.030 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2014 | 23 | 0.030 |
Why?
|
| Disease Progression | 2 | 2011 | 1610 | 0.030 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2014 | 53 | 0.030 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2014 | 59 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 1224 | 0.030 |
Why?
|
| RNA Interference | 1 | 2014 | 388 | 0.020 |
Why?
|
| Genetic Vectors | 2 | 2006 | 426 | 0.020 |
Why?
|
| Interleukin-15 Receptor alpha Subunit | 1 | 2012 | 6 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 564 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2012 | 141 | 0.020 |
Why?
|
| Epitopes | 1 | 2013 | 258 | 0.020 |
Why?
|
| Cell Count | 1 | 2012 | 195 | 0.020 |
Why?
|
| Apolipoprotein A-I | 1 | 2012 | 72 | 0.020 |
Why?
|
| Autoimmunity | 2 | 2006 | 195 | 0.020 |
Why?
|
| Inclusion Bodies | 1 | 2012 | 31 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 780 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2012 | 267 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2011 | 108 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2012 | 731 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2011 | 144 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 895 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2011 | 830 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 1815 | 0.020 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2007 | 29 | 0.020 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2007 | 35 | 0.020 |
Why?
|
| Whole-Body Irradiation | 1 | 2007 | 70 | 0.020 |
Why?
|
| Mesoderm | 1 | 2007 | 122 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2007 | 310 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 7387 | 0.020 |
Why?
|
| Time Factors | 2 | 2007 | 5576 | 0.020 |
Why?
|
| Thymidine Kinase | 1 | 2006 | 30 | 0.010 |
Why?
|
| Thymus Gland | 1 | 2007 | 205 | 0.010 |
Why?
|
| Phenotype | 1 | 2012 | 2638 | 0.010 |
Why?
|
| Dopamine | 1 | 2007 | 280 | 0.010 |
Why?
|
| Ligands | 1 | 2007 | 486 | 0.010 |
Why?
|
| Viral Vaccines | 1 | 2006 | 38 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 2006 | 191 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2006 | 178 | 0.010 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2006 | 169 | 0.010 |
Why?
|
| Chemotaxis | 1 | 2005 | 77 | 0.010 |
Why?
|
| Vaccines, Synthetic | 1 | 2005 | 59 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2006 | 213 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2006 | 168 | 0.010 |
Why?
|
| Injections, Intralesional | 1 | 2004 | 22 | 0.010 |
Why?
|
| Lymphopenia | 1 | 2004 | 31 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2006 | 523 | 0.010 |
Why?
|
| Aged | 2 | 2018 | 21760 | 0.010 |
Why?
|
| Viral Load | 1 | 2005 | 161 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 557 | 0.010 |
Why?
|
| Safety | 1 | 2004 | 138 | 0.010 |
Why?
|
| Nucleoside-Triphosphatase | 1 | 2003 | 7 | 0.010 |
Why?
|
| Fever | 1 | 2004 | 122 | 0.010 |
Why?
|
| Chemokine CCL20 | 1 | 2003 | 3 | 0.010 |
Why?
|
| Receptors, CCR6 | 1 | 2003 | 4 | 0.010 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2003 | 10 | 0.010 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2003 | 38 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2004 | 282 | 0.010 |
Why?
|
| Chemokines, CC | 1 | 2003 | 36 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2006 | 1026 | 0.010 |
Why?
|
| CD40 Ligand | 1 | 2003 | 79 | 0.010 |
Why?
|
| Cross-Linking Reagents | 1 | 2003 | 89 | 0.010 |
Why?
|
| Cell Separation | 1 | 2003 | 200 | 0.010 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2003 | 80 | 0.010 |
Why?
|
| Hepatitis C | 1 | 2005 | 186 | 0.010 |
Why?
|
| Transduction, Genetic | 1 | 2003 | 161 | 0.010 |
Why?
|
| Serine Endopeptidases | 1 | 2003 | 154 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2003 | 399 | 0.010 |
Why?
|
| Remission Induction | 1 | 2004 | 754 | 0.010 |
Why?
|
| Cell Death | 1 | 2003 | 257 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2006 | 985 | 0.010 |
Why?
|
| Middle Aged | 2 | 2018 | 29442 | 0.010 |
Why?
|
| Adult | 2 | 2018 | 29564 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2004 | 803 | 0.010 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2002 | 68 | 0.010 |
Why?
|
| Colony Count, Microbial | 1 | 2001 | 39 | 0.010 |
Why?
|
| Milk | 1 | 2001 | 56 | 0.010 |
Why?
|
| Abatacept | 1 | 2002 | 89 | 0.010 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2006 | 450 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2006 | 2896 | 0.010 |
Why?
|
| Lymphocyte Subsets | 1 | 2001 | 71 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 2001 | 215 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 1133 | 0.010 |
Why?
|
| Cattle | 1 | 2001 | 397 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2003 | 700 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 1131 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2003 | 707 | 0.010 |
Why?
|
| Peptides | 1 | 2003 | 669 | 0.010 |
Why?
|
| Mutation | 1 | 2011 | 4392 | 0.010 |
Why?
|
| Staphylococcus aureus | 1 | 2001 | 290 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2004 | 3213 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2001 | 1948 | 0.010 |
Why?
|
| Brain | 1 | 2007 | 2448 | 0.010 |
Why?
|